ORMP
ORAMED PHARMACEUTICALS INC.
NASDAQ · Healthcare · Biotechnology · US
$4.06
−0.25%Year over year
Reported trailing growth
- Revenue
- -100.0%
- EBITDA
- +3807.7%
- EBIT
- -6.2%
- EPS
- +793.4%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- -91.3%
Three-year CAGR
- Revenue
- -9.6%
- EBITDA
- +221.0%
- EBIT
- -18.1%
- Net income
- +240.5%
- EPS
- +230.6%
- Free cash flow
- -31.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026